Guide to Bone Marrow Transplant
Know about bone marrow transplant, who gets it done, symptoms, warning signs, risks, step by step procedure, donor matching, evaluating tests, recovery time line, immunizations, nutrition and more.
Written by Dr. Shaik Abdul Kalam
Reviewed by Dr. D Bhanu Prakash MBBS, AFIH, Advanced certificate in critical care medicine, Fellowship in critical care medicine
Last updated on 15th Oct, 2025
Introduction
If you or a loved one has been told you might need a bone marrow transplant, it’s natural to feel overwhelmed. This complete guide breaks down the science and the steps of a bone marrow transplant (also called a stem cell transplant) in clear, practical terms. You’ll learn who needs it, the types (autologous and allogeneic), how donors are matched, what to expect before, during, and after the procedure, common side effects like graft-versus-host disease, costs, recovery timelines, success rates, and the latest alternatives such as CAR T-cell therapy or gene therapy. This guide is designed to help you ask the right questions and make confident decisions. If you need to clarify symptoms or get a quick second opinion, you can consult a doctor online with Apollo24|7; and if lab tests are recommended along the way (like CBC or vitamin levels), Apollo24|7 also offers convenient home collection services.
What is a Bone Marrow (Stem Cell) Transplant?
Bone marrow vs. peripheral blood stem cells
A bone marrow transplant, medically termed a hematopoietic stem cell transplant (HSCT), replaces damaged or diseased blood-forming cells with healthy stem cells. These cells reside in bone marrow and mature into red blood cells, white blood cells, and platelets the essential components of blood.
In an autologous bone marrow transplant, you receive your own previously collected stem cells; in an allogeneic transplant, you receive cells from a donor whose tissue type closely matches yours. Transplant teams often use the phrase “Day 0” to mark the infusion of stem cells, much like a blood transfusion, not a surgical operation, and then monitor “engraftment,” the moment when the donor cells start producing healthy blood cells again.
Consult a Top Oncologist for Personalised Advice
How does engraftment work and how it monitored?
In blood cancers like leukaemia and lymphoma, high-dose chemotherapy (and sometimes radiation) first reduces or eradicates the cancer. The transplant then rescues your blood system and, in allogeneic cases, adds a natural immune effect known as “graft-versus-leukaemia/lymphoma,” where donor immune cells attack any remaining cancer cells. In noncancer conditions, such as severe aplastic anaemia or certain inherited blood disorders, the transplant replaces a failing or defective marrow with healthy blood production.
H3: Bone marrow vs. peripheral blood stem cells
H3: How engraftment works and how it’s monitored
Who May Need a Transplant?
Blood cancers commonly treated with transplant
A bone marrow transplant may be recommended for:
Blood cancers: acute and chronic leukaemias, Hodgkin and non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN).
Non-malignant disorders: severe aplastic anaemia, sickle cell disease, thalassemia, severe combined immunodeficiency (SCID), and certain metabolic or autoimmune conditions.
Noncancer conditions: who benefits and when?
The time of transplantation is important. For example, adults with acute myeloid leukaemia (AML) in first remission (CR1) with intermediate- or high-risk genetic features may be advised to pursue an allogeneic transplant when the disease burden is lowest, improving the chance of cure. Children with severe aplastic anaemia often do best with a matched sibling donor transplant early in the disease course. While, in myeloma, autologous transplant remains a standard consolidation therapy to deepen response, although it’s typically not curative.
When alternative therapies may be preferable
For eligible patients with relapsed/refractory B-cell leukaemias or lymphomas, CAR T-cell therapy can induce deep remissions that may delay or sometimes replace an immediate transplant. For sickle cell disease, emerging gene therapies are expanding options, but long-term data are still maturin.
H3: Blood cancers commonly treated with transplant
H3: Noncancer conditions: who benefits and when
H3: When alternative therapies may be preferable
Types of Transplant and Donor Sources
There are two main bone marrow transplant types:
Autologous: You are your own donor. Your stem cells are collected during remission, frozen, and later returned after high-dose chemotherapy. Common for multiple myeloma and some lymphomas.
Allogeneic: You receive stem cells from another person—ideally a matched sibling or unrelated donor—so you gain both blood system rescue and the graft-versus-cancer effect. Used for leukaemias, MDS, MPN, aplastic anaemia, and some inherited conditions.
PBSC, marrow harvest, and cord blood: choosing the graft
Donor sources include:
Peripheral blood stem cells (PBSC): Most common in adults; faster neutrophil engraftment but higher chronic GVHD risk than marrow harvest.
Bone marrow harvest: Often used in pediatric settings and when lowering GVHD risk is a priority .
Umbilical cord blood: Helpful when a close HLA match isn’t available; slower engraftment but more tolerant of mismatches.
Haploidentical options when matches are limited
Haploidentical (half-matched) transplants typically from a parent or child have grown rapidly thanks to modern GVHD prevention with post-transplant cyclophosphamide, expanding access for patients without fully matched donors.
H3: Autologous vs. allogeneic transplant (pros and cons)
H3: PBSC, marrow harvest, and cord blood: choosing the graft
H4: Haploidentical options when matches are limited
Donor Matching: How It Works?
Donor matching is essential, lets us know about donor, their experiences:
HLA basics and why a 10/10 match matters
Matching focuses on human leukocyte antigens (HLA) on white blood cells. A close match reduces the risk of graft rejection and graft-versus-host disease (GVHD). The ideal is a 10/10 HLA match (HLA-A, -B, -C, -DRB1, -DQB1) between donor and recipient. About 30% of patients have a matched sibling donor; the rest rely on unrelated donors in global registries, cord blood units, or haploidentical family donors.
Registry vs. family donors
Finding a donor involves:
Family testing: Parents and children are typically half-matches; siblings have a 25% chance of being a full match.
Registry search: National and international registries identify potential unrelated donors or cord blood units based on your HLA type, ancestry, and other factors.
What donors actually experience?
Donor experience: PBSC donors receive a few days of injections to “mobilise” stem cells, then undergo apheresis; bone marrow donors have a brief outpatient procedure under anaesthesia; recovery is usually quick.
H3: HLA basics and why a 10/10 match matters
H3: Registry vs. family donors
H3: What donors actually experience
Getting Ready: Evaluation, Tests, and Planning
Pre-transplant tests and clearances
Before a bone marrow transplant, you’ll undergo:
Diagnostic staging and response assessment (e.g., MRD testing in leukaemias). HLA typing and donor search initiation.
Organ function tests: heart (echocardiogram), lungs (PFTs), kidneys and liver (blood tests), infection screening (CMV, hepatitis, HIV).
Dental and dermatology checks to reduce infection risks.
Fertility preservation: sperm banking, egg/embryo freezing where appropriate.
Fertility, vaccines, and dental care
Vaccinations and dental clearance help lower infection risks. Your team will also discuss conditioning intensity myeloablative vs reduced-intensity conditioning (RIC)based on your age, comorbidities, and disease status.
Insurance, caregiver, and logistics planning
Planning essentials
Caregiver support and housing near the transplant centre for the first 100 days.
Insurance authorisations and financial counselling.
Nutrition optimisation and prehab (light exercise to build stamina).
Mental health and social support resources.
If you need quick access to baseline labs (CBC, kidney and liver panels, vitamin D), Apollo24|7 offers home collection servicesuseful when you’re juggling multiple appointments. If you’re unsure about fertility steps or timing, consult a doctor online with Apollo24|7 for guidance before admission.
H3: Pre-transplant tests and clearances
H3: Fertility, vaccines, and dental care
H3: Insurance, caregiver, and logistics planning
The Transplant Journey: Step by Step
The step by step journey involves:
Conditioning options: myeloablative vs RIC
Conditioning therapy: Over several days, you’ll receive high-dose chemotherapy (and sometimes targeted agents or radiation) to eradicate disease and prepare the marrow “niche” for donor cells. Choices include myeloablative regimens for younger/fitter patients and reduced-intensity conditioning for older adults or those with comorbidities.
Day 0 infusion: Healthy stem cells are thawed (if frozen) and infused through a central line
usually over 30–120 minutes. You’re awake; it feels like a blood transfusion.
Engraftment, transfusions, and chimerism
Engraftment: Neutrophil engraftment typically occurs around 10–20 days with PBSCs, 14–28 days with bone marrow, and may be longer with cord blood. You’ll receive growth factors, transfusions, and infection prophylaxis until counts recover. Early monitoring: Daily labs track absolute neutrophil count (ANC), platelets, kidney/liver function, and electrolytes. Chimerism tests may begin in weeks to months to confirm donor cell takeover.
Medications that protect against GVHD and infections
GVHD prophylaxis: Medications such as tacrolimus, methotrexate, mycophenolate, or post-transplant cyclophosphamide reduce GVHD risk.
H3: Conditioning options: myeloablative vs RIC
H3: Engraftment, transfusions, and chimerism
H3: Medications that protect against GVHD and infections
Risks, Side Effects, and Warning Signs
Short-term side effects and infection risk
Common early side effects include nausea, vomiting, mouth sores (mucositis), diarrhea or constipation, fatigue, temporary hair loss, taste changes, and skin rashes. The biggest early risks involve infections while white blood cells are low. Antibiotics, antivirals, and antifungals are routinely used as prophylaxis.
Acute and chronic GVHD explained
Graft-versus-host disease (GVHD) happens when donor immune cells attack normal tissues. Acute GVHD usually appears in the first 100 days, often affecting skin, gut, and liver; chronic GVHD can develop later, affecting eyes, mouth, lungs, skin, and joints. Depending on donor type and prophylaxis, moderate to severe acute GVHD occurs in roughly 30–50% of allogeneic recipients; chronic GVHD in about 30–50%. Other serious complications include veno-occlusive disease (VOD) of the liver, lung injuries, and rare secondary cancers.
Red flags that need immediate attention
Call for emergency immidiately for fever (≥38°C/100.4°F), uncontrolled diarrhea, severe abdominal pain, shortness of breath, new jaundice, sudden rashes, confusion, or chest pain. If symptoms persist beyond two weeks or worsen despite supportive care, consult a doctor online with Apollo24|7 for further evaluation and guidance on whether in-person assessment is needed.
H3: Short-term side effects and infection risk
H3: Acute and chronic GVHD explained
H3: Red flags that need immediate attention
Recovery Timeline and Daily Life
The recovery timeline, daily guidance and timeline to return to routine includes:
The first 100 days: what to expect
The “first 100 days” emphasize infection prevention and monitoring for GVHD and engraftment issues. Many people feel fatigued for weeks to months. Expect frequent follow-up visits for labs, transfusions, medication adjustments, and symptom checks.
Infection prevention, exercise, and routines
Daily life guidance includes:
Hygiene and exposure: Hand hygiene, avoiding sick contacts, food safety, and masking in crowded spaces are standard early on.
Activity: Short walks and gentle stretching help maintain stamina; increase gradually as counts recover.
Return to work/school: Often 3–6 months post-transplant, depending on your job and immune recovery. Discuss accommodations, remote work, or phased return with your team.
Emotional health: Anxiety is common. Peer support groups (in-person or virtual) and counseling help normalize the journey.
Returning to work or school: realistic timelines
Many centers use a vaccination schedule beginning around 3–6 months for inactivated vaccines and 24 months or later for selected live vaccines if there’s no active GVHD and immune recovery is adequate. Your team will personalize timing.
H3: The first 100 days: what to expect
H3: Infection prevention, exercise, and routines
H3: Returning to work or school: realistic timelines
Nutrition, Immunizations, and Lab Monitoring
Safe eating and hydration
Food safety is crucial early on. Focus on well-cooked proteins, pasteurized dairy, properly washed fruits/vegetables (or peel where appropriate), and avoid buffets or raw foods. Hydration supports kidney function, especially during medications like tacrolimus.
Key labs: CBC, chemistries, chimerism, CMV
Lab monitoring is done for:
CBC: tracks ANC and platelet recovery.
Chemistry panels: kidney, liver, electrolytes.
Viral monitoring: CMV and EBV PCR in allogeneic recipients.
Chimerism testing: shows the proportion of donor vs recipient cells over time [2][4].
Revaccination after transplant
Immunizations include:
Inactivated vaccines (e.g., influenza, pneumococcal, Tdap, hepatitis) typically restart at 3–6 months, with boosters as advised.
Live vaccines may be considered 24 months post-transplant if immune reconstitution is robust and there’s no active GVHD .
If your clinician requests routine labs (CBC, liver/kidney function) during follow-up, Apollo24|7 offers home collection to minimize travel and exposure. Ask your team for a transplant-specific “neutropenic diet” handout if recommended; centers differ on strictness but agree on avoiding high-risk foods early.
Unique insight: Taste changes can persist for months. Patients often tolerate cold, bland, or slightly tart foods better. Keep a “safe foods” list that you update weekly—small, consistent nutrition beats forcing large meals.
H3: Safe eating and hydration
H3: Key labs: CBC, chemistries, chimerism, CMV
H3: Revaccination after transplant
Outcomes, Survival, and Quality of Life
Survival by disease and transplant type
Outcomes vary by disease, stage, donor type, age, and comorbidities. Examples from large registries and clinical guidance:
Allogeneic transplant for AML in first remission can achieve long-term survival in ~50–65% of appropriately selected adults, with reduced relapse compared to chemotherapy alone.
Autologous transplant in multiple myeloma improves progression-free survival by 1–2 years on average and remains a standard of care, often combined with maintenance therapy.
Severe aplastic anemia outcomes with matched sibling donor transplant in younger patients exceed 80–90% survival in many series .
Factors that influence outcomes
Key drivers of success include disease risk (cytogenetics, minimal residual disease), donor match quality (HLA), patient fitness (age, HCT-CI comorbidity index), and center experience. GVHD-free, relapse-free survival (GRFS) is an evolving metric that better reflects “how well” life looks after transplant.
GRFS and patient-centered measures
Quality of life generally improves within 6–12 months for many patients, although chronic GVHD can delay recovery. Ongoing survivorship care addresses fatigue, fertility, hormones, bone health, and emotional wellbeing.
H3: Survival by disease and transplant type
H3: Factors that influence outcomes
H3: GRFS and patient-centered measures
Alternatives and New Frontiers (CAR T, Gene Therapy)
Alternatives depend on diagnosis and timing:
CAR T-cell therapy: FDA-approved for several relapsed/refractory B-cell leukemias and lymphomas, achieving high complete response rates in selected settings and sometimes delaying or replacing immediate allogeneic transplant .
Targeted therapies: FLT3, IDH inhibitors in AML; BTK inhibitors in certain lymphomas/CLL; these may bridge to transplant or offer durable control in some patients.
Gene therapy/editing: Emerging options for sickle cell disease and thalassemia have gained approvals, with growing long-term data.
Research frontiers include improved GVHD prevention (e.g., post-transplant cyclophosphamide in haploidentical settings), microbiome modulation to reduce infections and GVHD, and “maintenance” strategies to lower relapse risk (e.g., FLT3 inhibitors post-HSCT in AML).
H3: When CAR T may replace or delay transplant
H3: Gene therapy for inherited blood disorders
H3: Trials and innovations to ask about
Costs, Support Services, and Choosing a Center
Understanding and planning costs
Costs vary widely by country and transplant type. In the U.S., total episode costs (evaluation through early recovery) often range from USD 200,000–400,000+; in India, typical estimates are roughly INR 10–25 lakhs for autologous and INR 20–40 lakhs for allogeneic transplants, depending on hospital, donor source, and complications. Insurance coverage, charity programs, and government schemes can offset expenses—ask to meet a financial counselor early.
What to ask when choosing a transplant center?
Choosing a center
Experience and volume in your disease.
Accreditation (FACT/JACIE) and outcomes reporting.
Access to donor search services and cell processing.
Multidisciplinary support (fertility, rehab, psychosocial care).
Access to clinical trials.
Caregiver, housing, and mental health resources
Support services include caregiver housing, travel assistance, school/work documentation, and survivorship clinics. If your condition does not improve after trying conservative steps during recovery, book a physical visit to a doctor with Apollo24|7 for coordinated follow-up or second-opinion referrals.
H3: Understanding and planning costs
H3: What to ask when choosing a transplant center
H3: Caregiver, housing, and mental health resources
Myths and Facts You Should Know
Myth: Bone marrow transplant is always a surgery. Fact: The transplant itself is an infusion, like a blood transfusion; no bone drilling is done during the infusion].
Myth: You must have a perfectly matched sibling. Fact: Many successful transplants use unrelated donors, cord blood, or haploidentical family donors.
Myth: Life halts indefinitely. Fact: Recovery takes months, but many patients return to work/school in 3–12 months with appropriate precautions.
Myth: GVHD is inevitable. Fact: Modern prevention and treatment strategies significantly reduce severity and improve outcomes.
H3: Common misconceptions corrected
H3: Practical truths patients wish they’d known earlier
Conclusion
A bone marrow transplant is one of the most powerful tools in modern medicine for curing or controlling blood cancers and serious blood disorders. While the idea can feel daunting, understanding the path evaluation, donor matching, conditioning, infusion, engraftment, and recovery can transform fear into a focused plan. Your care team will tailor choices such as autologous vs allogeneic transplant, graft source, and conditioning intensity to your diagnosis, age, and overall health. Clear communication about risks like infection and GVHD, plus practical steps for nutrition, hygiene, and exercise, will help you navigate the critical first 100 days and beyond. Many people return to work or school and resume favorite activities within months, and survivorship support continues to improve long-term quality of life. If you have lingering questions or want a second opinion before committing to a center, consult a doctor online with Apollo24|7.
Consult a Top Oncologist for Personalised Advice
Consult a Top Oncologist for Personalised Advice
Dr. Amit Choraria
Surgical Oncologist
18 Years • MBBS, MS (Surgery) Fellow, Surgical Oncology, Tata Medical Center (FSO) Fellow, European Board of Surgery (Surgical Oncology) (FEBS) Fellow, Minimal Access Surgery (FMAS) Fellow, Indian Association of Gastrointestinal Endosurgeons (FIAGES) UICC Fellow, Royal Marsden NHS, London, UK Visiting Scholar, Plastic Reconstructive Surgery, CGMH, Taiwan Fellow, Robotic Surgical Oncology, Vattikuti Foundation, USA
Kolkata
Apollo Multispeciality Hospitals , Kolkata, Kolkata
(50+ Patients)
Dr. Sanchayan Mandal
Medical Oncologist
17 Years • MBBS, DrNB( MEDICAL ONCOLOGY), DNB (RADIOTHERAPY),ECMO. PDCR. ASCO
Kolkata
MCR SUPER SPECIALITY POLY CLINIC & PATHOLOGY, Kolkata
Dr. Rupam Manna
Radiation Specialist Oncologist
4 Years • MBBS MD(RADIO THERAPY)
Barasat
Diab-Eat-Ease, Barasat
Dr. Prashant Chandra Das
Surgical Oncologist
15 Years • MBBS (MKCG Medical college) MCh (Surgical Oncology, Kidwai memorial institute of Oncology, Bangalore) MS (General Surgery, BHU Varanasi) Fellowship in Minimal Access Surgery ( FMAS). ESSO Course On Minimally Invasive Esophagectomy & Gastrectomy (UMC, Utrecht, Netherlands). Trained in Robotic and Laparoscopic Cancer Surgery.
Bhubaneswar
Apollo Hospitals Old Sainik School Road, Bhubaneswar
(25+ Patients)
Dr. Harsh J Shah
Surgical Oncologist
15 Years • MS, MCh (GI), DrNB (GI)
Ahmedabad
Apollo Hospitals Gandhinagar, Ahmedabad
More articles from Bone Cancer
Frequently Asked Questions
1) Is a bone marrow transplant a surgery?
No. The transplant is an infusion of stem cells through an IV line, similar to a blood transfusion. Collection from donors can be via apheresis (blood draw) or a short bone marrow harvest procedure. Long-tail keyword used: bone marrow transplant procedure.
2) How long does bone marrow transplant recovery take?
Early recovery spans the first 100 days, focusing on engraftment and infection prevention. Many patients resume work or school between 3–12 months, depending on complications. Long-tail keyword used: bone marrow transplant recovery time.
3) What is graft-versus-host disease (GVHD)?
GVHD occurs when donor immune cells attack the recipient’s tissues. It can be acute (first 100 days) or chronic (later). Preventive medicines and early treatment reduce severity. Long-tail keyword used: what is graft-versus-host disease.
4) When should I consider alternatives like CAR T-cell therapy?
Some relapsed/refractory leukemias and lymphomas, CAR T can induce deep remissions and delay or replace immediate transplant. Decisions depend on disease, timing, and trial availability. Long-tail keyword used: CAR T-cell therapy vs transplant.
5) How can I minimize infection risk after transplant?
Follow food safety and hygiene guidance, take prophylactic medications as prescribed, avoid sick contacts, and stay current with your post-transplant vaccination schedule. If you develop fever ≥38°C, contact your team or consult a doctor online with Apollo24|7.